STAT3 and metabolic syndrome: The inhibition of the STAT3 signaling pathway has shown promise in reducing visceral obesity (Su et al., 2020), countering metabolic syndrome development (Hua et al., 2018), and preventing obesity-induced neuroinflammation (Zhou et al., 2020).